





	CLSI QSE: Organization			
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)	
	4.1 Organization and management responsibility4.2 Quality management system	8 Management system requirements	 4.4 Quality management system and its processes 5.1 Leadership and commitment 5.2 Policy 5.3 Organizational roles, responsibilities, and authorities 6 Planning 7.1 Resources 	
Related CLSI Documents	4.15 Management review	8.9 Management reviews	9.3 Management review	
Quality Management System	ns*			
QMS01-A4	Quality Management System: A Model for Laboratory Services; Approved Guideline—Fourth Edition			
QMS14-A	Quality Management System: Leadership and Management Roles and Responsibilities; Approved Guideline			
Automation and Informatics				
AUTO13-A2	Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline—Second Edition			
Molecular Methods	Molecular Methods			
MM19-A	M19-A Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline			
MM20-A	Quality Management for Molecular Genetic Testing; Approved Guideline			
Point-of-Care Testing	sting			
POCT04-Ed3	Essential Tools for Implementation and Manage	Essential Tools for Implementation and Management of a Point-of-Care Testing Program, Third Edition		
POCT07-A	Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline			
QMS01-A4 QMS14-A Automation and Informatics AUTO13-A2 Molecular Methods MM19-A MM20-A Point-of-Care Testing POCT04-Ed3	Quality Management Systems* QMS01-A4 Quality Management System: A Model for Laboratory Services; Approved Guideline—Fourth Edition QMS14-A Quality Management System: Leadership and Management Roles and Responsibilities; Approved Guideline Automation and Informatics AUT013-A2 Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline—Second Edition Molecular Methods MM19-A Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline MM20-A Quality Management for Molecular Genetic Testing; Approved Guideline Point-of-Care Testing POCT04-Ed3 Essential Tools for Implementation and Management of a Point-of-Care Testing Program, Third Edition			

	CLSI QSE: Customer Focus			
WCLSI	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)	
,			5.1.2 Customer focus	
Related CLSI Documents	4.7 Advisory services		9.1.2 Customer satisfaction	
Quality Management Syster	ns*			
QMS01-A4	Quality Management System: A Model for Labo	oratory Services; Approved Guideline—Fourth Ed	ition	
Automation and Informatics				
AUTO13-A2	Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline—Second Edition			
Immunology and Ligand Ass	nd Ligand Assay			
I/LA23-A	Assessing the Quality of Immunoassay Systems: Radioimmunoassays and Enzyme, Fluorescence, and Luminescence Immunoassays; Approved Guideline			
Molecular Methods				
MM19-A	Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline			
MM20-A	Quality Management for Molecular Genetic Testing; Approved Guideline			

Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline

Point-of-Care Testing

POCT07-A

	CLSI QSE: Facilities and Safety			
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)	
Related CLSI Documents	5.2 Accommodation and environmental conditions	6.3 Facilities and Environmental Conditions	7.1.3 Infrastructure 7.1.4 Environment for the operation of processes	
Quality Management System	ns*			
QMS01-A4	Quality Management System: A Model for Labo	oratory Services; Approved Guideline—Fourth	Edition	
QMS04-Ed3	Laboratory Design, Third Edition			
GP05-A3	Clinical Laboratory Waste Management; Appro	oved Guideline—Third Edition		
GP17-A3	Clinical Laboratory Safety; Approved Guideline	—Third Edition		
Automation and Informatics	5			
AUTO13-A2	Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline—Second Edition			
Immunology and Ligand Assay				
I/LA21-A2	Clinical Evaluation of Immunoassays; Approved Guideline—Second Edition			
Microbiology	Microbiology			
M29-A4	Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Fourth Edition			
M36-A	Clinical Use and Interpretation of Serologic Test	ts for Toxoplasma gondii; Approved Guideline		
M43-A	Methods for Antimicrobial Susceptibility Testing	g for Human Mycoplasmas; Approved Guidelir	ne	
M48-A	Laboratory Detection and Identification of Mycobacteria; Approved Guideline			
M54-A	Principles and Procedures for Detection of Fungi in Clinical Specimens—Direct Examination and Culture; Approved Guideline			
Molecular Methods	Molecular Methods			
MM19-A	Establishing Molecular Testing in Clinical Labor	ratory Environments; Approved Guideline		
MM20-A	Quality Management for Molecular Genetic Te	Quality Management for Molecular Genetic Testing; Approved Guideline		
Point-of-Care Testing	e Testing			

Essential Tools for Implementation and Management of a Point-of Care Testing Program, Third Edition

Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline

Abbreviations: ISO, International Organization for Standardization; QSE, quality system essential.

POCT04-Ed3

POCT07-A

CLSI CLSI	

	CLSI QSE: Personnel		
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)
•	5.1 Personnel	6.2 Personnel	7.1.2 People

Related CLSI Documents	5.1 Personnel	6.2 Personnel	7.1.2 People	
Quality Management Systems*				
QMS01-A4	Quality Management System: A Model	for Laboratory Services; Approved Guide	eline—Fourth Edition	
QMS03-Ed4	Training and Competence Assessment, F	Fourth Edition		
Automation and Informatics	5			
AUTO13-A2	Laboratory Instruments and Data Mand Operation, and Monitoring; Approved C	agement Systems: Design of Software U Guideline — Second Edition	lser Interfaces and End-User Software Systems Validation,	
Molecular Methods	Molecular Methods			
MM19-A	Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline			
MM20-A	Quality Management for Molecular Genetic Testing; Approved Guideline			
Point-of-Care Testing	Point-of-Care Testing			
POCT04-Ed3	Essential Tools for Implementation and	Management of a Point-of-Care Testing	Program, Third Edition	
POCT07-A	Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline			
POCT10-A2	Physician and Nonphysician Provider-Performed Microscopy Testing; Approved Guideline—Second Edition			
POCT12-A3	Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline—Third Edition		ved Guideline—Third Edition	
POCT13-Ed3	Glucose Monitoring in Settings Without Laboratory Support, Third Edition			

		CLSI QSE: Purchasing and Inventor	y
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	
, 0 = 0.		6.6 Externally provided products and	
	4.4 Service agreements	services	
	4.5 Examination by referral laboratories	7.1 Review of requests, tenders,	8

	4.5 Examination by referral laboratories4.6 External services and supplies	7.1 Review of requests, tenders, and contracts	8.4 Control of externally provided processes, products and services	
Quality Management Systems*				
QMS01-A4	O1-A4 Quality Management System: A Model for Laboratory Services; Approved Guideline—Fourth Edition			
QMS05-A2	Quality Management System: Qualifying, Selecting, and Evaluating a Referral Laboratory; Approved Guideline—Second Edition			

Automation and Informatics

Clinical Evaluation of Immunoassays; Approved Guideline—Second Edition

Immunology and Ligand Assay

I/LA21-A2

*	3 3 11
Molecular Methods	
MM19-A Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline	
Point-of-Care Testing	
POCT04-Ed3 Essential Tools for Implementation and Management of a Point-of-Care Testing Program, 3rd Edition	
POCT07-A Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline	
POCT09-A Selection Criteria for Point-of-Care Testing Devices; Approved Guideline	

Abbreviations: ISO, International Organization for Standardization; QSE, quality system essential.

ISO 9001:2015 Clause(s)

	S
,	

	CLSI QSE: Equipment				
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)		
•	5.3 Laboratory equipment, reagents, and consumables	6.4 Equipment	7.1.5 Monitoring and measuring resources		
en	ms*				
	Quality Management System: A Model for Laboratory Services; Approved Guideline—Fourth Edition				

Related CLSI Documents	and consumables	6.4 Equipment	resources
Quality Management Syster	ns*		
QMS01-A4	Quality Management System: A Model for Labo	oratory Services; Approved Guideline—Fourth Edi	ition
QMS13-A	Quality Management System: Equipment; App	roved Guideline	
Automation and Informatics			
AUTO01-A	Laboratory Automation: Specimen Container/S	Specimen Carrier; Approved Standard	
AUTO02-A2	Laboratory Automation: Bar Codes for Specime	n Container Identification; Approved Standard—	Second Edition
AUTO13-A2	Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline—Second Edition		
Hematology			
H42-A2	Enumeration of Immunologically Defined Cell Populations by Flow Cytometry; Approved Guideline—Second Edition		
H43-A2	Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline—Second Edition		
H57-A	Protocol for the Evaluation, Validation, and Implementation of Coagulometers; Approved Guideline		
Immunology and Ligand Assay			
I/LA21-A2	Clinical Evaluation of Immunoassays; Approved Guideline—Second Edition		
I/LA33-A	Validation of Automated Systems for Immunohematological Testing Before Implementation; Approved Guideline		
Molecular Methods			
MM19-A	Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline		
Newborn Screening			
NBS04-Ed2	Newborn Screening by Tandem Mass Spectrom	etry, Second Edition	



CLSI QSE: Equipment (Continued)			
ISO 15189:2012 Clause(s) ISO 17025:2017 Clause(s) ISO 9001:2015 Clause(s)			
5.3 Laboratory equipment, reagents, and consumables	6.4 Equipment	7.1.5 Monitoring and measuring resources	

Related CLSI Documents

Related CEST Documents	and consumables	0.4 Equipment	resources
Point-of-Care Testing			
POCT02-A	Implementation Guide of POCT01 for Health (Care Providers; Approved Guideli	ne
POCT04-Ed3	Essential Tools for Implementation and Management of a Point-of-Care Testing Program, Third Edition		
POCT07-A	Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline		
POCT09-A	Selection Criteria for Point-of-Care Testing Dev	vices; Approved Guideline	
POCT10-A2	Physician and Nonphysician Provider-Perform	ed Microscopy Testing; Approved	Guideline—Second Edition
POCT13-Ed3	Glucose Monitoring in Settings Without Labor	ratory Support, Third Edition	



CLSI	CLSI QSE: Process Management		
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)
	5.4 Pre-examination processes5.5 Examination processes5.6 Ensuring quality of examination results5.7 Post-examination processes5.8 Reporting results	 7 Process requirements 7.2.2 Validation of Methods Annex A Metrological Traceability 7.3 Sampling 7.4 Handling of test or calibration items 7.7 Ensuring the validity of results 	8.1 Operational planning and control8.2 Requirements for products and services8.3 Design and Development of Products and Services
Related CLSI Documents	5.9 Releasing results	7.8 Reporting of results	8.5 Production and service provision
Quality Management System	ns*		
QMS01-A4	Quality Management System: A Model for Laboratory Services; Approved Guideline—Fourth Edition		
Automation and Informatic	;		
AUTO02-A2	Laboratory Automation: Bar Codes for Specimen Container Identification; Approved Standard—Second Edition		
AUTO08-A	Managing and Validating Laboratory Information Systems; Approved Guideline		
AUTO09-A	Remote Access to Clinical Laboratory Diagnostic Devices via the Internet; Approved Standard		
AUTO10-A	Autoverification of Clinical Laboratory Test Results; Approved Guideline		
AUTO11-Ed2	IT Security of In Vitro Diagnostic Instruments and Software Systems, Second Edition		
ALITO12-A	Specimen Labels, Content and Location Fonts, and Label Orientation, Approved Standard		

AUTO02-A2 AUTO08-A AUTO09-A AUTO10-A AUTO11-Ed2 AUTO12-A Specimen Labels: Content and Location, Fonts, and Label Orientation; Approved Standard Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, AUTO13-A2 Operation, and Monitoring; Approved Guideline—Second Edition Specification for Low-Level Protocol to Transfer Messages Between Clinical Laboratory Instruments and Computer Systems; Approved LIS01-A2 Standard—Second Edition Specification for Transferring Information Between Clinical Laboratory Instruments and Information Systems; Approved Standard— LIS02-A2 Second Edition Standard Guide for Documentation of Clinical Laboratory Computer Systems LIS04-A



	CLSI QSE: Process Management (Continued)			
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)	
Polated CISI Deguments	 5.4 Pre-examination processes 5.5 Examination processes 5.6 Ensuring quality of examination results 5.7 Post-examination processes 5.8 Reporting results 	7 Process requirements 7.2.2 Validation of Methods Annex A Metrological Traceability 7.3 Sampling 7.4 Handling of test or calibration items 7.7 Ensuring the validity of results	 8.1 Operational planning and control 8.2 Requirements for products and services 8.3 Design and Development of Products and Services 	
Related CLSI Documents Clinical Chemistry and Toxic		7.8 Reporting of results	8.5 Production and service provision	
C52-Ed3		abovatory Third Edition		
C56-A	Toxicology and Drug Testing in the Medical Laboratory, Third Edition Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline			
C58-A	Assessment of Fetal Lung Maturity by the Lamellar Body Count; Approved Guideline			
General Laboratory				
GP15-A3	Cervicovaginal Cytology Based on the Papanicolaou Technique; Approved Guideline—Third Edition			
GP16-A3	Urinalysis; Approved Guideline—Third Edition			
GP20-A2	Fine-Needle Aspiration Biopsy (FNAB) Techniques; Approved Guideline—Second Edition			
GP23-Ed2	Nongynecological Cytology Specimens: Preexamination, Examination, and Postexamination Processes, Second Edition			
GP33-Δ	Accuracy in Patient and Samnle Identification: Annroyed Guideline			

C52-Ed3	Toxicology and Drug Testing in the Medical Laboratory, Third Edition		
C56-A	Hemolysis, Icterus, and Lipemia/Turbidity Indices as Indicators of Interference in Clinical Laboratory Analysis; Approved Guideline		
C58-A	Assessment of Fetal Lung Maturity by the Lamellar Body Count; Approved Guideline		
General Laboratory			
GP15-A3	Cervicovaginal Cytology Based on the Papanicolaou Technique; Approved Guideline—Third Edition		
GP16-A3	Urinalysis; Approved Guideline — Third Edition		
GP20-A2	Fine-Needle Aspiration Biopsy (FNAB) Techniques; Approved Guideline—Second Edition		
GP23-Ed2	Nongynecological Cytology Specimens: Preexamination, Examination, and Postexamination Processes, Second Edition		
GP33-A	Accuracy in Patient and Sample Identification; Approved Guideline		
GP34-A	Validation and Verification of Tubes for Venous and Capillary Blood Specimen Collection; Approved Guideline		
GP39-A6	Tubes and Additives for Venous and Capillary Blood Specimen Collection; Approved Standard—Sixth Edition		
GP41-Ed7	Collection of Diagnostic Venous Blood Specimens, Seventh Edition		
GP42-A6	Procedures and Devices for the Collection of Diagnostic Capillary Blood Specimens; Approved Standard—Sixth Edition		
GP44-A4	Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests; Approved Guideline—Fourth Edition		



CLSI QSE: Process Management (Continued)			
ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)	
5.4 Pre-examination processes	7 Process requirements 7.2.2 Validation of Methods		
5.5 Examination processes5.6 Ensuring quality of examination results	Annex A Metrological Traceability 7.3 Sampling 7.4 Handling of test or calibration	8.1 Operational planning and control8.2 Requirements for products and services	
5.7 Post-examination processes5.8 Reporting results5.9 Releasing results	items 7.7 Ensuring the validity of results 7.8 Reporting of results	8.3 Design and Development of Products and Services8.5 Production and service provision	

Related CLSI Documents

Hematology	
H02-A5	Procedures for the Erythrocyte Sedimentation Rate Test; Approved Standard—Fifth Edition
H07-A3	Procedure for Determining Packed Cell Volume by the Microhematocrit Method; Approved Standard—Third Edition
H15-A3	Reference and Selected Procedures for the Quantitative Determination of Hemoglobin in Blood; Approved Standard—Third Edition
H20-A2	Reference Leukocyte (WBC) Differential Count (Proportional) and Evaluation of Instrumental Methods; Approved Standard—Second Edition
H21-A5	Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays; Approved Guideline—Fifth Edition
H26-A2	Validation, Verification, and Quality Assurance of Automated Hematology Analyzers; Approved Standard—Second Edition
H30-A2	Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline—Second Edition
H42-A2	Enumeration of Immunologically Defined Cell Populations by Flow Cytometry; Approved Guideline—Second Edition
H43-A2	Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline—Second Edition
H47-A2	One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline—Second Edition
H52-A2	Red Blood Cell Diagnostic Testing Using Flow Cytometry; Approved Guideline—Second Edition
H54-A	Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline
H56-A	Body Fluid Analysis for Cellular Composition; Approved Guideline
H57-A	Protocol for the Evaluation, Validation, and Implementation of Coagulometers; Approved Guideline

	CLSI QSE: Process Management (Continued)		
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)
, 0201	5.4 Pre-examination processes5.5 Examination processes5.6 Ensuring quality of examination results5.7 Post-examination processes5.8 Reporting results	 7 Process requirements 7.2.2 Validation of Methods Annex A Metrological Traceability 7.3 Sampling 7.4 Handling of test or calibration items 7.7 Ensuring the validity of results 	8.1 Operational planning and control8.2 Requirements for products and services8.3 Design and Development of Products and Services
Related CLSI Documents	5.9 Releasing results	7.8 Reporting of results	8.5 Production and service provision
Hematology (Continued)			
H58-A	Platelet Function Testing by Aggregometry;	Approved Guideline	

Hematology (Continued)			
H58-A	Platelet Function Testing by Aggregometry; Approved Guideline		
H59-A	Quantitative D-dimer for the Exclusion of Venous Thromboembolic Disease; Approved Guideline		
H60-A	Laboratory Testing for the Lupus Anticoagulant; Approved Guideline		
Immunology and Ligand As	say		
I/LA02-A2	Quality Assurance of Laboratory Tests for Autoantibodies to Nuclear Antigens: (1) Indirect Fluorescence Assay for Microscopy and (2) Microtiter Enzyme Immunoassay Methods; Approved Guideline—Second Edition		
I/LA20-Ed3	Analytical Performance Characteristics, Quality Assurance, and Clinical Utility of Immunological Assays for Human Immunoglobulin E Antibodies of Defined Allergen Specificities, Third Edition		
I/LA21-A2	Clinical Evaluation of Immunoassays; Approved Guideline—Second Edition		
I/LA23-A	Assessing the Quality of Immunoassay Systems: Radioimmunoassays and Enzyme, Fluorescence, and Luminescence Immunoassays; Approved Guideline		
I/LA25-A2	Maternal Serum Screening; Approved Standard—Second Edition		
I/LA26-A2	Performance of Single Cell Immune Response Assays; Approved Guideline—Second Edition		
I/LA28-A2	Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays; Approved Guideline—Second Edition		
I/LA29-A	Detection of HLA-Specific Alloantibody by Flow Cytometry and Solid Phase Assays; Approved Guideline		
I/LA30-A	Immunoassay Interference by Endogenous Antibodies; Approved Guideline		



	CLSI QSE: Process Management (Continued)		
CLSI	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)
, 0201		7 Process requirements	
	5.4 Pre-examination processes	7.2.2 Validation of Methods	
	5.5 Examination processes	Annex A Metrological Traceability	8.1 Operational planning and control
	5.6 Ensuring quality of examination	7.3 Sampling	8.2 Requirements for products and
	results	7.4 Handling of test or calibration	services
	5.7 Post-examination processes5.8 Reporting results	items 7.7 Ensuring the validity of results	8.3 Design and Development of Products and Services
Related CLSI Documents	5.9 Releasing results	7.8 Reporting of results	8.5 Production and service provision
Immunology and Ligand Ass		7.0 Reporting or results	o.s rroddetion and service provision
I/LA33-A		ohematological Testing Before Implementation	; Approved Guideline
I/LA34-A	Design and Validation of Immunoassays for Assessment of Human Allergenicity of New Biotherapeutic Drugs; Approved Guideline		
Method Evaluation			
EP05-A2	Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition		
EP06-A	Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline		
EP07-A2	Interference Testing in Clinical Chemistry; Approved Guideline—Second Edition		
EP09-A3	Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline—Third Edition		
EP10-A3-AMD	Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline—Third Edition		
EP12-A2	User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline—Second Edition		
EP14-Ed3	Evaluation of Commutability of Processed Samples, Third Edition		
EP15-Ed3	User Verification of Precision and Estimation of Bias, Third Edition		
EP17-A2	Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition		
EP18-A2	Risk Management Techniques to Identify and Control Laboratory Error Sources; Approved Guideline—Second Edition		
EP19-R	A Framework for NCCLS Evaluation Protocols; A Report		
EP21-A	Estimation of Total Analytical Error for Clinical Laboratory Methods; Approved Guideline		



CLSI QSE: Process Management (Continued)				
ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)		
 5.4 Pre-examination processes 5.5 Examination processes 5.6 Ensuring quality of examination results 5.7 Post-examination processes 5.8 Reporting results 	7 Process requirements 7.2.2 Validation of Methods Annex A Metrological Traceability 7.3 Sampling 7.4 Handling of test or calibration items 7.7 Ensuring the validity of results	8.1 Operational planning and control8.2 Requirements for products and services8.3 Design and Development of Products and Services		
5.9 Releasing results	7.8 Reporting of results	8.5 Production and service provision		

Related CLSI Documents

Method Evaluation (Continued)
EP23-A	Laboratory Quality Control Based on Risk Management; Approved Guideline
EP24-A2	Assessment of the Diagnostic Accuracy of Laboratory Tests Using Receiver Operating Characteristic Curves; Approved Guideline—Second Edition
EP25-A	Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline
EP26-A	User Evaluation of Between-Reagent Lot Variation; Approved Guideline
EP27-A	How to Construct and Interpret an Error Grid for Quantitative Diagnostic Assays; Approved Guideline
ЕРЗО-А	Characterization and Qualification of Commutable Reference Materials for Laboratory Medicine; Approved Guideline
EP31-A-IR	Verification of Comparability of Patient Results Within One Health Care System; Approved Guideline (Interim Revision)
EP32-R	Metrological Traceability and Its Implementation; A Report
Microbiology	
M02-Ed13	Performance Standards for Antimicrobial Disk Susceptibility Tests, Thirteenth Edition
M07-Ed11	Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Eleventh Edition
M11-Ed9	Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 9th Edition
M15-A	Laboratory Diagnosis of Blood-borne Parasitic Diseases; Approved Guideline
M22-A3	Quality Control for Commercially Prepared Microbiological Culture Media; Approved Standard—Third Edition



CLSI	QSE: Process Management (Conti	nued)
ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)
	7 Process requirements	
5.4 Pre-examination processes	7.2.2 Validation of Methods	
5.5 Examination processes	Annex A Metrological Traceability	8.1 Operational planning and control
5.6 Ensuring quality of examination	7.3 Sampling	8.2 Requirements for products and
results	7.4 Handling of test or calibration	services
5.7 Post-examination processes	items	8.3 Design and Development of Products
5.8 Reporting results	7.7 Ensuring the validity of results	and Services
5.9 Releasing results	7.8 Reporting of results	8.5 Production and service provision

Related CLSI Documents

Microbiology (Continued)	
M23-Ed5	Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters, Fifth Edition
M24-Ed3	Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, 3rd Edition
M26-A	Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline
M27-A4	Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Fourth Edition
M28-A2	Procedures for the Recovery and Identification of Parasites From the Intestinal Tract; Approved Guideline—Second Edition
M29-A4	Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Fourth Edition
M34-A	Western Blot Assay for Antibodies to Borrelia burgdorferi; Approved Guideline
M35-A2	Abbreviated Identification of Bacteria and Yeast; Approved Guideline—Second Edition
M36-A	Clinical Use and Interpretation of Serologic Tests for Toxoplasma gondii; Approved Guideline
M38-Ed3	Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Third Edition
M39-A4	Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline—Fourth Edition
M40-Ed2	Quality Control of Microbiological Transport Systems, Second Edition
M41-A	Viral Culture; Approved Guideline
M43-A	Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline
M44-Ed3	Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts, 3rd Edition

APP.	
W C	

	CLSI QSE: Process Management (Continued)		
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)
V OLOI	 5.4 Pre-examination processes 5.5 Examination processes 5.6 Ensuring quality of examination results 5.7 Post-examination processes 5.8 Reporting results 	7 Process requirements 7.2.2 Validation of Methods Annex A Metrological Traceability 7.3 Sampling 7.4 Handling of test or calibration items 7.7 Ensuring the validity of results	 8.1 Operational planning and control 8.2 Requirements for products and services 8.3 Design and Development of Products and Services
Related CLSI Documents	5.9 Releasing results	7.8 Reporting of results	8.5 Production and service provision
Microbiology (Continued)			
M45-Ed3	Methods for Antimicrobial Dilution and Disk S Second Edition	usceptibility Testing of Infrequently Isolated or F	astidious Bacteria; Approved Guideline—
M47-A	Principles and Procedures for Blood Cultures; Approved Guideline		
M48-Ed2	Laboratory Detection and Identification of Mycobacteria, 2nd Edition		
M50-A	Quality Control for Commercial Microbial Identification Systems; Approved Guideline		
M51-A	Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi; Approved Guideline		
M53-A	Criteria for Laboratory Testing and Diagnosis of Human Immunodeficiency Virus Infection; Approved Guideline		
M54-A	Principles and Procedures for Detection of Fungi in Clinical Specimens—Direct Examination and Culture; Approved Guideline		
M60-Ed1	Performance Standards for Antifungal Suscept	ibility Testing of Yeasts, First Edition	
M62-Ed1	Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, 1st Edition		
M100-Ed29	Performance Standards for Antimicrobial Susceptibility Testing, Twenty-Ninth Edition		
Molecular Methods			
MM01-A3	Molecular Methods for Clinical Genetics and C	ncology Testing; Approved Guideline—Third Ed	ition
MM03-Ed3	Molecular Diagnostic Methods for Infectious D	Diseases, Third Edition	
MM05-A2	Nucleic Acid Amplification Assays for Molecular Hematopathology; Approved Guideline—Second Edition		
MM06-A2	Quantitative Molecular Methods for Infectious	s Diseases; Approved Guideline—Second Edition	



CLS	l QSE: Process Management (Con	tinued)
ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)
	7 Process requirements	
5.4 Pre-examination processes	7.2.2 Validation of Methods	
5.5 Examination processes	Annex A Metrological Traceability	8.1 Operational planning and control
5.6 Ensuring quality of examination	7.3 Sampling	8.2 Requirements for products and
results	7.4 Handling of test or calibration	services
5.7 Post-examination processes	items	8.3 Design and Development of Products
5.8 Reporting results	7.7 Ensuring the validity of results	and Services
5.9 Releasing results	7.8 Reporting of results	8.5 Production and service provision

Related CLSI Documents

Molecular Methods (Co	ontinued)
MM07-A2	Fluorescence In Situ Hybridization Methods for Clinical Laboratories; Approved Guideline—Second Edition
MM09-A2	Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline—Second Edition
MM10-A	Genotyping for Infectious Diseases: Identification and Characterization; Approved Guideline
MM11-A	Molecular Methods for Bacterial Strain Typing; Approved Guideline
MM12-A	Diagnostic Nucleic Acid Microarrays; Approved Guideline
MM13-A	Collection, Transport, Preparation, and Storage of Specimens for Molecular Methods; Approved Guideline
MM14-A2	Design of Molecular Proficiency Testing/External Quality Assessment; Approved Guideline—Second Edition
MM17-Ed2	Validation and Verification of Multiplex Nucleic Acid Assays, Second Edition
MM18-Ed2	Interpretive Criteria for Identification of Bacteria and Fungi by Targeted DNA Sequencing, Second Edition
MM19-A	Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline
MM20-A	Quality Management for Molecular Genetic Testing; Approved Guideline
MM22-A	Microarrays for Diagnosis and Monitoring of Infectious Diseases; Approved Guideline

	CLS	QSE: Process Management (Cont	inued)	
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)	
Related CLSI Documents	 5.4 Pre-examination processes 5.5 Examination processes 5.6 Ensuring quality of examination results 5.7 Post-examination processes 5.8 Reporting results 5.9 Releasing results 	7 Process requirements 7.2.2 Validation of Methods Annex A Metrological Traceability 7.3 Sampling 7.4 Handling of test or calibration items 7.7 Ensuring the validity of results 7.8 Reporting of results	 8.1 Operational planning and control 8.2 Requirements for products and services 8.3 Design and Development of Products and Services 8.5 Production and service provision 	
Newborn Screening				
NBS01-A6	Blood Collection on Filter Paper for Newborn :	Screening Programs; Approved Standard—Sixth	Edition	
NBS02-A2	Newborn Screening Follow-up; Approved Guideline—Second Edition			
NBS03-A	Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns; Approved Guideline			
NBS04-Ed2	Newborn Screening by Tandem Mass Spectrometry, Second Edition			
NBS05-A	Newborn Screening for Cystic Fibrosis; Approved Guideline			
NBS06-A	Newborn Blood Spot Screening for Severe Combined Immunodeficiency by Measurement of T-cell Receptor Excision Circles; Approved Guideline			
Point-of-Care Testing				
POCT02-A	Implementation Guide of POCT01 for Health	Care Providers; Approved Guideline		
POCT04-Ed3	Essential Tools for Implementation and Management of a Point-of-Care Testing Program, Third Edition			
POCT05-A	Performance Metrics for Continuous Interstiti	Performance Metrics for Continuous Interstitial Glucose Monitoring; Approved Guideline		
POCT07-A		Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline		
РОСТО8-А	Quality Practices in Noninstrumented Point-of-Care Testing: An Instructional Manual and Resources for Health Care Workers; Approved Guideline			
POCT09-A	Selection Criteria for Point-of-Care Testing Devices; Approved Guideline			
POCT10-A2	Physician and Nonphysician Provider-Perform	ed Microscopy Testing; Approved Guideline—Sec	cond Edition	



	CLS	I QSE: Process Management (Con	tinued)
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)
V CLJI	 5.4 Pre-examination processes 5.5 Examination processes 5.6 Ensuring quality of examination results 5.7 Post-examination processes 5.8 Reporting results 	7 Process requirements 7.2.2 Validation of Methods Annex A Metrological Traceability 7.3 Sampling 7.4 Handling of test or calibration items 7.7 Ensuring the validity of results	8.1 Operational planning and control 8.2 Requirements for products and services 8.3 Design and Development of Products and Services
Related CLSI Documents	5.9 Releasing results	7.8 Reporting of results	8.5 Production and service provision
Point-of-Care Testing (Contin	nued)		
POCT12-A3	Point-of-Care Blood Glucose Testing in Acute	and Chronic Care Facilities; Approved Guideline	—Third Edition
POCT13-Ed3	Glucose Monitoring in Settings Without Laboratory Support, Third Edition		
POCT14-A	Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline		
Veterinary Medicine			
VET01-Ed5	Performance Standards for Antimicrobial Dis	k and Dilution Susceptibility Tests for Bacteria Is	olated From Animals, Fifth Edition
VET02-A3	Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents; Approved Guideline—Third Edition		
VET03-A	Methods for Antimicrobial Disk Susceptibility	Testing of Bacteria Isolated From Aquatic Anim	als; Approved Guideline
VET04-A	Methods for Broth Dilution Susceptibility Test	Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Approved Guideline	
VET03/VET04-Ed2	Performance Standards for Antimicrobial Susceptibility Testing of Bacteria Isolated From Aquatic Animals, Second Edition		
VET05-R	Generation, Presentation, and Application of	Antimicrobial Susceptibility Test Data for Bacter	ria of Animal Origin; A Report

		CLSI QSE: Documents and Record	de	
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)	
, old	4.3 Document control	7.5 Technical records 7.11 Control of data and information management 8.3. Control of management system documents (Option A)		
Related CLSI Documents		8.4 Control of records (Option A)	7.5 Documented information	
Quality Management Syster				
QMS01-A4		Quality Management System: A Model for Laboratory Services; Approved Guideline—Fourth Edition		
QMS02-A6	Quality Management System: Development and Management of Laboratory Documents; Approved Guideline—Sixth Edition			
Automation and Informatics				
AUTO13-A2	Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline—Second Edition			
Immunology and Ligand Ass	say			
I/LA21-A2	Clinical Evaluation of Immunoassays; Approved Guideline—Second Edition			
I/LA33-A	Validation of Automated Systems for Immunohematological Testing Before Implementation; Approved Guideline			
Microbiology				
M07-Ed11	Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Eleventh Edition			
Molecular Methods				
MM19-A	Establishing Molecular Testing in Clinical Labo	oratory Environments; Approved Guideline		
MM20-A	Quality Management for Molecular Genetic Testing; Approved Guideline			
Point-of-Care Testing				
POCT07-A	Quality Management: Approaches to Reducir	ng Errors at the Point of Care; Approved Guidelin	е	
POCT10-A2	Physician and Nonphysician Provider-Perform	ed Microscopy Testing; Approved Guideline—Sec	cond Edition	
POCT12-A3	Point-of-Care Blood Glucose Testing in Acute of	and Chronic Care Facilities; Approved Guideline-	–Third Edition	
POCT13-Ed3	Glucose Monitoring in Settings Without Labo	ratory Support, Third Edition		

Ouality Management System: A Model for Laboratory Services: Approved Guideline—Fourth Edition

CI

Related CLSI Documents

Point-of-Care Testing

POCT01-A2

POCT07-A

QMS01-A4

use(s) ISO 9001:2015 Clause(s)
ormation 7.5 Documented information
_

Quality	/ Management Systems*	
---------	-----------------------	--

QM301-A4	Quality Management System. A Model for Eduboratory Services, Approved Guideline Tourin Edition	
Automation and Info	ormatics	
AUTO03-A2	Laboratory Automation: Communications With Automated Clinical Laboratory Systems, Instruments, Devices, and Information Systems; Approved Standard—Second Edition	
AUTO04-A	Laboratory Automation: Systems Operational Requirements, Characteristics, and Information Elements; Approved Standard	
AUTO05-A	Laboratory Automation: Electromechanical Interfaces; Approved Standard	
AUTO07-A	Laboratory Automation: Data Content for Specimen Identification; Approved Standard	
AUTO13-A2	Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline—Second Edition	
LIS01-A2	Specification for Low-Level Protocol to Transfer Messages Between Clinical Laboratory Instruments and Computer Systems; Approved Standard—Second Edition	
LIS02-A2	Specification for Transferring Information Between Clinical Laboratory Instruments and Information Systems; Approved Standard—Second Edition	
Immunology and Lig	and Assay	
I/LA21-A2	Clinical Evaluation of Immunoassays; Approved Guideline—Second Edition	
Molecular Methods		
MM19-A	Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline	
MM20-A	Quality Management for Molecular Genetic Testing; Approved Guideline	

Abbreviations: ISO, International Organization for Standardization; QSE, quality system essential.

Point-of-Care Connectivity; Approved Standard—Second Edition

Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline



	CLSI QSE: Nonconforming Event Management		
M CLSI	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)
Related CLSI Documents	4.8 Resolution of complaints4.9 Identification and control of nonconformities4.10 Corrective action	7.9 Complaints 7.10 Nonconforming work 8.7 Corrective actions (Option A)	8.7 Control of nonconforming outputs
Quality Management System		o.r corrective actions (option ry	e., control of horizontonning outputs
QMS01-A4	Quality Management System: A Model for Laboratory Services; Approved Guideline—Fourth Edition		
QMS11-Ed2	Nonconforming Event Management, Second Edition		
Automation and Informatics	Automation and Informatics		
AUTO13-A2	Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline—Second Edition		
Method Evaluation			
EP18-A2	Risk Management Techniques to Identify and Control Laboratory Error Sources; Approved Guideline—Second Edition		
Molecular Methods	Molecular Methods		
MM19-A	Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline		
MM20-A	Quality Management for Molecular Genetic Testing; Approved Guideline		
Point-of-Care Testing			
POCT07-A	Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline		

	CLSI QSE: Assessments			
	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)	
Related CLSI Documents	4.11 Preventive action 4.14 Evaluation and audits	8.5 Actions to address risks and opportunities (Option A) 8.8 Internal audits (Option A)	5.1.1 General 9.1 Monitoring, measurement, analysis and evaluation 9.1.3 Analysis and evaluation8.4 Analysis of data	
Quality Management Syster	ns*			
QMS01-A4	Quality Management System: A Model for La	boratory Services; Approved Guideline—Fourth E	dition	
QMS15-A	Assessments: Laboratory Internal Audit Progr	Assessments: Laboratory Internal Audit Program; Approved Guideline		
QMS24-Ed3	Using Proficiency Testing and Alternative Assessment to Improve Medical Laboratory Quality, 3rd Edition			
Hematology	Hematology			
H57-A	Protocol for the Evaluation, Validation, and Implementation of Coagulometers; Approved Guideline			
Immunology and Ligand Ass	say			
I/LA21-A2	Clinical Evaluation of Immunoassays; Approv	Clinical Evaluation of Immunoassays; Approved Guideline—Second Edition		
I/LA25-A2	Maternal Serum Screening; Approved Standa	Maternal Serum Screening; Approved Standard—Second Edition		
Method Evaluation				
EP10-A3-AMD	Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline—Third Edition			
EP18-A2	Risk Management Techniques to Identify and Control Laboratory Error Sources; Approved Guideline—Second Edition			
Molecular Methods				
MM19-A	Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline			
MM20-A	Quality Management for Molecular Genetic Testing; Approved Guideline			
Point-of-Care Testing				
POCT07-A	Quality Management: Approaches to Reducir	ng Errors at the Point of Care; Approved Guideline		
POCT09-A	Selection Criteria for Point-of-Care Testing Devices; Approved Guideline			

	CLSI QSE: Continual Improvement			
WCLSI.	ISO 15189:2012 Clause(s)	ISO 17025:2017 Clause(s)	ISO 9001:2015 Clause(s)	
Related CLSI Documents	4.12 Continual improvement	8.6 Improvement (Option A)	10 Improvement	
Quality Management Syste	ms*			
QMS01-A4	Quality Management System: A Model for L	aboratory Services; Approved Guideline—Fourtl	h Edition	
QMS12-A	Development and Use of Quality Indicators	Development and Use of Quality Indicators for Process Improvement and Monitoring of Laboratory Quality; Approved Guideline		
QMS06-A3	Quality Management System: Continual Im	provement; Approved Guideline—Third Edition		
Automation and Information	is .			
AUTO13-A2	Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline—Second Edition			
Hematology				
H26-A2	Validation, Verification, and Quality Assurar	nce of Automated Hematology Analyzers; Appro	ved Standard—Second Edition	
Immunology and Ligand As	ssay			
I/LA21-A2	Clinical Evaluation of Immunoassays; Approved Guideline—Second Edition			
I/LA25-A2	Maternal Serum Screening; Approved Standard—Second Edition			
Method Evaluation				
EP18-A2	Risk Management Techniques to Identify and Control Laboratory Error Sources; Approved Guideline—Second Edition			
Molecular Methods				
MM19-A	Establishing Molecular Testing in Clinical La	Establishing Molecular Testing in Clinical Laboratory Environments; Approved Guideline		
MM20-A	Quality Management for Molecular Genetic	Quality Management for Molecular Genetic Testing; Approved Guideline		
Point-of-Care Testing				
POCT07-A	Quality Management: Approaches to Reducing Errors at the Point of Care; Approved Guideline			

ISO Document Titles	
ISO 15189:2012	Medical laboratories Requirements for quality and competence
ISO 17025:2017	General requirements for the competence of testing and calibration laboratories
ISO 9001:2015	Quality management systems Requirements

